...
首页> 外文期刊>Cancer causes and control: CCC >Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study
【24h】

Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study

机译:护士健康研究中的非甾体类抗炎药,对乙酰氨基酚和皮肤癌风险

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with lower risk of certain cancers, but data on the effect on skin cancer risk have been limited and contradictory. We prospectively examined whether use of NSAIDS or acetaminophen was associated with a lower risk of skin cancer in women. Methods The 92,125 Caucasian women in the Nurses' Health Study provided information on aspirin use in 1980. Other NSAIDs and acetaminophen were added in 1990. Medication use, frequency, and quantity were reassessed on biennial questionnaires. Through 2008, we confirmed 658 melanoma cases, 1,337 squamous cell carcinoma (SCC) cases, and had 15,079 self-reports of basal cell carcinoma (BCC). We used COX proportional hazards models to compute relative risks (RR) adjusted for known skin cancer risk factors. Results Neither aspirin nor non-aspirin NSAID use was associated with a lower risk of melanoma, SCC, or BCC, even for women with high quantity, frequency, or duration of use. Instead, we observed an increased risk of melanoma among current aspirin users (RR = 1.32, 95 % CI 1.03-1.70), though an increase of similar magnitude among past users and lack of a dose-response effect did not support a pharmacologic mechanism. We observed a mild reduction in SCC risk in current acetaminophen users (RR = 0.88, 95 % CI 0.75-1.02), with a linear decrease in risk with greater frequency of use (p = 0.04). Conclusions Aspirin and other NSAIDs were not associated with a lower risk of melanoma, SCC, or BCC in women. Our large, prospective study does not support a chemoprotective effect of NSAIDs against skin cancers.
机译:目的非甾体类抗炎药(NSAIDs)与某些癌症的风险较低相关,但有关皮肤癌风险影响的数据有限且相互矛盾。我们前瞻性地检查了使用NSAIDS或对乙酰氨基酚是否可以降低女性患皮肤癌的风险。方法1980年在护士健康研究中的92125名白人妇女提供了有关阿司匹林使用的信息。1990年增加了其他非甾体抗炎药和对乙酰氨基酚的使用。两年一次的问卷调查重新评估了药物的使用,频率和数量。到2008年,我们确诊了658例黑色素瘤病例,1,337例鳞状细胞癌(SCC)病例,并报告了1,079例基底细胞癌(BCC)的自我报告。我们使用COX比例风险模型来计算针对已知皮肤癌风险因素调整的相对风险(RR)。结果使用阿司匹林和非阿司匹林非甾体抗炎药均不会降低黑色素瘤,SCC或BCC的风险,即使对于使用量大,使用频率高或使用时间长的女性也是如此。相反,我们观察到目前使用阿司匹林的患者中黑色素瘤的风险增加(RR = 1.32,95%CI 1.03-1.70),尽管过去的患者中相似程度的升高以及缺乏剂量反应效应并不支持药理机制。我们观察到当前对乙酰氨基酚使用者的SCC风险有轻度降低(RR = 0.88,95%CI 0.75-1.02),并且随着使用频率的增加,风险呈线性下降(p = 0.04)。结论阿司匹林和其他NSAID与女性黑色素瘤,SCC或BCC的较低风险无关。我们的大型前瞻性研究不支持NSAID对皮肤癌的化学保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号